CELZ
Creative Medical Technology Holdings, Inc.
There isn't enough reported data to score CELZ yet.
CELZ Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
CELZ's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
CELZ PE Valuation
CELZ has no meaningful PE right now: it lost money over the past year.
CELZ Forward outlook
There aren't enough analyst estimates for CELZ to show an outlook.
CELZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.92 | +$1.05 |
| Q2 2026 | -$2.00 | +$1.08 |
| Q1 2026 | -$2.07 | +$1.70 |
| Q4 2025 | -$2.52 | +$1.19 |
CELZ lost $1.92 per share over the past year, a smaller loss than the year before.
CELZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3K | 0% |
| Q4 2024 | $3K | 0% |
| Q4 2023 | $3K | -84% |
| Q3 2023 | $6K | -89% |
| Q4 2022 | $18.6K | -73% |
| Q3 2022 | $55K | +450% |
| Q4 2021 | $67.8K | +287% |
| Q3 2021 | $10K | -87% |
CELZ's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -64859% | -2002 points |
| Q1 2025 | -55349% | N/A |
| Q4 2024 | -62858% | -3797 points |
| Q2 2024 | -20316% | N/A |
| Q4 2023 | -59061% | -25309 points |
| Q3 2023 | -25720% | -23864 points |
| Q4 2022 | -33752% | -31579 points |
| Q3 2022 | -1855% | +6479 points |
CELZ's operating margin was −64859% last quarter, down 5798 points from the same quarter a year ago, near the bottom of its range since 2019.
CELZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7M | -$495.7K |
| Q2 2026 | -$1.5M | -$313.5K |
| Q1 2026 | -$1.3M | +$268.2K |
| Q4 2025 | -$1.9M | +$12K |
| Q3 2025 | -$1.2M | -$183K |
| Q2 2025 | -$1.2M | +$310.6K |
| Q1 2025 | -$1.6M | -$694.7K |
| Q4 2024 | -$1.9M | -$54.6K |
CELZ has burned cash in almost every quarter: −$6M over the past year, against −$6M the year before.
CELZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +80% | +3M shares |
| 1 year | +158% | +4.1M shares |
| 3 years | +373% | +5.3M shares |
CELZ has 7M diluted shares, up 158% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $10,000 |
| Q4 2024 | — |
CELZ hasn't bought back shares in the past year.
CELZ Net Leverage
CELZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CELZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 2.7 | Oversold |
CELZ's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
CELZ PE vs Healthcare Sector
CELZ has no meaningful PE right now: it lost money over the past year.
CELZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.77 | 19% below |
| 20 week MA | $0.94 | 34% below |
| 50 week MA | $1.62 | 62% below |
| 100 week MA | $2.28 | 73% below |
| 200 week MA | $3.45 | 82% below |
CELZ is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
CELZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $225.0 | $19.5 | -91% |
| 2021 | $19.5 | $20.1 | +3.1% |
| 2022 | $20.1 | $3.70 | -82% |
| 2023 | $3.70 | $4.61 | +25% |
| 2024 | $4.61 | $2.31 | -50% |
| 2025 | $2.31 | $2.10 | -9.1% |
| 2026 YTD | $2.10 | $0.62 | -70% |
CELZ has finished lower in four of the last six years. It's down 70% so far in 2026.